Fubotv earnings beat by $0.10, revenue topped estimates
SCOTTSDALE, Ariz. - Journey Medical Corporation (NASDAQ:DERM), currently valued at $148.63 million, will be added to the Russell 2000 and Russell 3000 indexes effective after U.S. markets close on June 27, 2025, the company announced Tuesday. According to InvestingPro data, the stock appears to be trading above its Fair Value based on comprehensive analysis.
The dermatology-focused pharmaceutical company, which markets FDA-approved prescription medications for skin conditions, expects the inclusion to enhance its visibility among investors and institutions.
"The launch of Emrosi, our FDA-approved treatment for inflammatory lesions of rosacea in adults, is off to a strong start," said Claude Maraoui, Journey Medical’s Co-Founder, President and CEO, in a press release statement. The company’s stock has reflected this momentum, surging 42% over the past six months, with analysts setting price targets between $9 and $11, according to InvestingPro data.
The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index represents a subset focused on small-cap companies. Approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, according to the company.
Journey Medical currently markets eight branded FDA-approved prescription drugs for dermatological conditions. The company’s flagship product, Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules), received FDA approval for treating inflammatory rosacea lesions in adults.
The Russell indexes, maintained by FTSE Russell, undergo annual reconstitution to ensure they accurately represent their market segments. The indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for investment strategies. For deeper insights into Journey Medical’s financial health, growth prospects, and detailed valuation metrics, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Journey Medical Corporation reported its Q1 2025 earnings, highlighting a net revenue of $13.1 million, which exceeded expectations by $1.5 million. Despite this revenue beat, the company reported a net loss of $0.18 per share, missing the expected loss of $0.10 per share. The company’s gross margin improved significantly to 64%, up from 54% in the previous year. Journey Medical also successfully launched AMROCI, a new rosacea treatment, contributing approximately $2 million to the quarterly revenue. The company emphasized the importance of AMROCI’s launch, noting its inclusion in the National Rosacea Society’s treatment algorithms, which could enhance clinical adoption.
Moreover, Journey Medical announced that its rosacea treatment, Emrosi, demonstrated consistent efficacy regardless of patient body weight in two Phase 3 clinical trials. This finding is significant as it allows the drug to be prescribed without weight-based dosage adjustments. The trials showed that Emrosi was superior to both placebo and doxycycline in treating moderate-to-severe rosacea. The company also highlighted that Emrosi is the lowest FDA-approved oral dose of minocycline that does not require weight-based dosing adjustments. These recent developments underscore Journey Medical’s efforts to innovate and expand its presence in the dermatology market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.